Livzon Pharmaceutical Group Inc Market Cap ($2.45 Billion)
Market Cap & Net Worth: Livzon Pharmaceutical Group Inc (000513)
Livzon Pharmaceutical Group Inc market cap. Livzon Pharmaceutical Group Inc (SHE:000513) has a market capitalization of $2.45 Billion (CN¥16.77 Billion) as of October 31, 2026. Listed on the SHE stock exchange, this China-based company holds position #5286 globally and #861 in its home market, demonstrating a 9.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Livzon Pharmaceutical Group Inc's stock price CN¥28.52 by its total outstanding shares 588100054 (588.10 Million).
Livzon Pharmaceutical Group Inc Market Cap History (2015–2026)
Livzon Pharmaceutical Group Inc market cap history from 2015 to 2026. Data shows growth from $1.74 Billion to $2.45 Billion (3.86% CAGR). Check Livzon Pharmaceutical Group Inc share price for real-time trading data and today's change.
Livzon Pharmaceutical Group Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Livzon Pharmaceutical Group Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 000513 cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.25x
Livzon Pharmaceutical Group Inc's market cap is 0.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.47x
Livzon Pharmaceutical Group Inc's market cap is 1.47 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.82 Billion | $7.65 Billion | $784.35 Million | 0.24x | 2.32x |
| 2017 | $2.66 Billion | $8.53 Billion | $4.43 Billion | 0.31x | 0.60x |
| 2018 | $1.35 Billion | $8.86 Billion | $1.08 Billion | 0.15x | 1.25x |
| 2019 | $2.44 Billion | $9.38 Billion | $1.30 Billion | 0.26x | 1.87x |
| 2020 | $3.02 Billion | $10.52 Billion | $1.71 Billion | 0.29x | 1.76x |
| 2021 | $3.07 Billion | $12.06 Billion | $1.78 Billion | 0.25x | 1.73x |
| 2022 | $2.58 Billion | $12.63 Billion | $1.91 Billion | 0.20x | 1.35x |
| 2023 | $2.90 Billion | $12.43 Billion | $1.95 Billion | 0.23x | 1.49x |
| 2024 | $3.27 Billion | $11.81 Billion | $2.06 Billion | 0.28x | 1.59x |
| 2025 | $2.97 Billion | $11.91 Billion | $2.02 Billion | 0.25x | 1.47x |
Competitor Companies of 000513 by Market Capitalization
Companies near Livzon Pharmaceutical Group Inc in the global market cap rankings as of October 31, 2026. See Livzon Pharmaceutical Group Inc (000513) balance sheet quality index to understand what proportion of total assets are financed by equity.
Key companies related to Livzon Pharmaceutical Group Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Livzon Pharmaceutical Group Inc (2015–2026)
Market capitalization of Livzon Pharmaceutical Group Inc from 2015 to today. Between 2015 and today, Livzon Pharmaceutical Group Inc's market cap moved from $1.74 Billion to $ 2.45 Billion, with a yearly change of 3.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.45 Billion | -17.24% |
| 2025 | CN¥2.97 Billion | -9.32% |
| 2024 | CN¥3.27 Billion | +12.58% |
| 2023 | CN¥2.90 Billion | +12.38% |
| 2022 | CN¥2.58 Billion | -15.89% |
| 2021 | CN¥3.07 Billion | +1.84% |
| 2020 | CN¥3.02 Billion | +23.71% |
| 2019 | CN¥2.44 Billion | +80.45% |
| 2018 | CN¥1.35 Billion | -49.24% |
| 2017 | CN¥2.66 Billion | +46.28% |
| 2016 | CN¥1.82 Billion | +4.84% |
| 2015 | CN¥1.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Livzon Pharmaceutical Group Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.45 Billion USD |
| MoneyControl | $2.45 Billion USD |
| MarketWatch | $2.45 Billion USD |
| marketcap.company | $2.45 Billion USD |
| Reuters | $2.45 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Livzon Pharmaceutical Group Inc
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more